Paul Grena, DO
Cardiovascular Disease · Yardley, PANPI 1851365308
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $22,090 of the $30,107 with a category attached, or 73.4%. 30 manufacturers reported payments, led by Eli Lilly at 58.2% of the total. Reporting peaked in 2023 at $17,484 and has fallen 65.3% since, to $6,071 in 2025. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 400 payments — averaging $75.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$18K
- Merck$7K
- Janssen Research & Development, LLC$1K
- Amgen$878
- Novartis$725
- Pfizer$512
- plus $3K from 24 others
Across 142 payments — averaging $11,052 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$798K
- Novartis$501K
- Janssen Research & Development, LLC$182K
- Kiniksa Pharmaceuticals, Ltd.$37K
- Amarin Pharma, Inc.$17K
- Pfizer$11K
- plus $24K from 6 others
What the payments were for
- Travel & lodging$22,09073%
- Food & beverage$7,96626%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 70 | $17,537 |
| Merck | 50 | $6,520 |
| Janssen Research & Development, LLC | 14 | $1,346 |
| Amgen | 48 | $878 |
| Novartis | 42 | $725 |
| Pfizer | 36 | $512 |
| Johnson & Johnson | 21 | $379 |
| AstraZeneca | 17 | $303 |
| Novo Nordisk | 12 | $240 |
| Amarin Pharma, Inc. | 23 | $233 |
| Esperion Therapeutics, Inc. | 13 | $226 |
| Lexicon Pharmaceuticals, Inc. | 6 | $135 |
| E.r. Squibb & Sons, L.L.C. | 8 | $128 |
| Cleerly, Inc. | 1 | $127 |
| Kiniksa Pharmaceuticals International, PLC | 6 | $101 |
| Lilly USA, LLC | 2 | $93 |
| Boston Scientific | 4 | $86 |
| Scpharmaceuticals Inc. | 3 | $72 |
| Bayer | 4 | $62 |
| Boehringer Ingelheim | 4 | $62 |
| Impulse Dynamics (USA) Inc. | 2 | $57 |
| Edwards Lifesciences | 2 | $45 |
| Inspire Medical Systems, Inc. | 2 | $44 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Janssen Scientific Affairs, LLC | 1 | $37 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Portola Pharmaceuticals, LLC | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Endotronix, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cleerly Ischemia$127
- Cleerly Labs$127
How this compares
$30,107 in reported general payments places this provider in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 367 | $398,139 |
| XareltoRivaroxaban | 125 | $140,255 |
| Repatha SureclickEvolocumab | 156 | $131,526 |
| EntrestoSacubitril/Valsartan | 91 | $107,059 |
| FarxigaDapagliflozin Propanediol | 54 | $44,316 |
| Praluent PenAlirocumab | 25 | $28,718 |
| Rosuvastatin Calcium | 1,667 | $28,047 |
| Irbesartan | 539 | $18,122 |
| VascepaIcosapent Ethyl | 17 | $13,111 |
| Ezetimibe | 379 | $10,585 |
| Metoprolol Succinate | 498 | $9,037 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 220 | $8,674 |
| Valsartan | 103 | $7,868 |
| Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide | 253 | $7,359 |
| CrestorRosuvastatin Calcium | 16 | $6,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $512 | $398,139367 claims |
| Johnson & JohnsonXarelto | $379 | $140,255125 claims |
| NovartisEntresto | $725 | $107,05991 claims |
| AstraZenecaFarxiga, Crestor | $303 | $50,92570 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Yardley
- Hemal GadaWormleysburg$1.8M
- Benjamin KalsmithPgh$1.7M
- Peter KoweyWynnewood$1.5M
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Rhian DaviesYork$853K
- Sarang MangalmurtiBryn Mawr$728K
- Sabahat BokhariAllentown$578K
- George GabrielPittsburgh$563K
- Rajesh DaveCamp Hill$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.